Vision, mission and strategy
Our vision
A world where all patients with rare immunologic diseases can lead long and healthy lives.
Our mission
We leverage our unique immunomodulating technology platform to develop innovative, lifesaving and life altering therapies, bring these to the patients with rare conditions who need them, and generate value to society at large.
Strategic priorities
Hansa’s mission is to become a global leader in rare diseases through the development of innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
Commercialize IDEFIRIX® in first indication and markets
Successfully launch Hansa's first authorized product IDEFIRIX in Europe.
Secure FDA approval and launch in the U.S.
Geographical Expansion.
Advance ongoing imlifidase clinical programs
Achieve approval/usage of imlifidase in follow-on indications
Broaden the label beyond kidney transplantation.
Expand IgG-cleaving enzyme technology
Expand IgG-cleaving enzyme technology platform into gene therapy.
Develop next generation IgG-cleaving enzymes for repeat usage
Build a focused, integrated, agile and empowered international organization and seek partnerships to accelerate growth and reduce risk
Søren Tulstrup, President and CEO, Hansa Biopharma
Bringing our innovative science to those with urgent unmet medical needs
"Everything we do at Hansa Biopharma is driven by our mission in life: to develop lifesaving and life altering immunomodulating therapies, bring them to the patients with rare conditions who need them, and generate value to society at large."
Read more